scholarly journals Squamous cell carcinoma of the pterygopalatine fossa - A case report

2016 ◽  
Vol 6 (23) ◽  
pp. 173-176
Author(s):  
Vlad Budu ◽  
Mihail Tusaliu ◽  
Alexandru Coman ◽  
Ioan Bulescu
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Resection ◽  
Surgical Techniques ◽  
Pterygopalatine Fossa ◽  
Transnasal Approach ◽  
Selective Embolization ◽  
Maxillary Nerve ◽  
Anatomical Space

Abstract The pterygopalatine fossa is an inverted pyramid-shaped space of the viscerocranium, protected by bony structures. Surgical access to this anatomical space is difficult, especially for tumor resection. There are numerous open surgical techniques for accessing this space, but nowadays, minimally-invasive endoscopic approaches are preferred in order to increase postoperative quality of life and reduce postoperative morbidities.The tumors of the pterygopalatine fossa can be benign or malignant, and can occur primarily in the fossa or as secondary extensions from the surrounding regions through the multiple canals and foramina in its walls. Squamous cell carcinomas of this space have been described to appear as extensions from the nasopharynx, the paranasal sinuses or through perineural extension from the cutaneous branches of the maxillary nerve.In this paper the authors present a rare case of squamous cell carcinoma of the pterygopalatine fossa, which was excised in an endoscopic transnasal approach after preoperative selective embolization.

Radiation-Induced Carcinoma in a Hemangioma

1979 ◽  
Vol 87 (5) ◽  
pp. 584-586 ◽  
Author(s):  
John M. Fredrickson ◽  
J.S.J. Haight ◽  
Arnold M. Noyek
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Surgical Techniques ◽  
Radiation Induced

A case of squamous cell carcinoma arising in repeatedly irradiated buccal hemangioma is reported, and the surgical techniques used in reconstructing the cheek and lips are described.

ETIOLOGICAL, CLINICAL AND PATHOLOGICAL PROGNOSTIC MARKERS IN HEAD AND NECK CANCERS TREATED WITH CONCURRENT CHEMO-RADIATION

2017 ◽  
Vol 2 (01) ◽  
Author(s):  
Ankur Yadav Sarkar ◽  
Piyush Kumar ◽  
Arvind Kumar Chauhan ◽  
Milan Jaiswal ◽  
D. P. Singh
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Surgical Techniques ◽  
Response Assessment ◽  
Concurrent Chemotherapy ◽  
Head And Neck Cancers ◽  
Related Factors

Introduction: Advanced squamous cell carcinoma of head and neck are usually treated with surgery and/or radiotherapy. Integration of chemotherapy also plays an important role for improving organ preservation. Various prognostic factors help in selecting the appropriate treatment regimen for the individual patient. The present study was conducted to identify the prognostic factors in head and neck cancers. Material and Methods: Previously untreated 33 patients of squamous cell carcinoma were selected. They were treated with concurrent chemotherapy and radiotherapy. The response assessment was analyzed in terms of various patient, tumor and treatment related factors. Statistical analysis was done using chi square test. Results: Etiological factors- tobacco and alcohol, non-vegetarean diet were associated with a poor outcome but were not statistically significant. Clinical factors- higher N-stage (p=0.04) and AJCC stage (p=0.03) were found to be significant predictors of poor prognosis while T-stage was not found significant, probably due to short follow-up. Patients receiving less than 5 cycles of concurrent chemotherapy had a significantly worse prognosis (p=0.04). Among the pathological factors that were studied, high mitotic index (Grade III or more) were associated with a significantly poorer prognosis (p=0.04). Conclusion: Many clinico pathological factors have been correlated with locoregional control in head and neck cancers. These can be used to individualize the treatment by different surgical techniques, various radiotherapy dose and fractionation schedules and chemotherapy protocols.

Prognostic value of programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma

2020 ◽  
Author(s):  
Qun Zhang ◽  
Feng Li ◽  
Peng Cai ◽  
Hongwei Li ◽  
Hongmei Yin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Tumor Resection ◽  
Programmed Death Ligand 1 ◽  
Cox Regression Analysis ◽  
Programmed Death ◽  
L1 Protein

Abstract Background To investigate the expression of PD-L1(programmed death-ligand 1)in patients with esophageal squamous cell carcinoma (ESCC) and its clinical significance. Methods The tissue expression of PD-L1 protein in 139 cases of ESCC and 50 adjacent non-malignant epithelial tissues (> 5 cm from the tumor resection margins) were identified by immunohistochemical staining. Subsequently, the relationship between expression and the observed clinical characteristics was analyzed. Results The positive expression rate of PD-L1 protein was increased in tumor tissues compared to that of adjacent noncancerous mucosa tissues (40.3% vs. 22.0%, P < 0.05). The findings also indicated that PD-L1 protein expression had no significant correlation with age, gender, tumor location, differentiation and lymph node (N) status (P > 0.05). The 91 months follow-up Kaplan-Meier survival analysis showed that patients in positively expressed PD-L1 group experienced a lower survival rate compared to their negatively expressed PD-L1 counterparts (32.1% vs. 48.2%, P < 0.05). The COX regression analysis results suggested that PD-L1 represented an independent prognosis factor for ESCC. Conclusions The findings indicated that PD-L1 plays an important role in the progression of ESCC and might represent a potential therapeutic and prognostic target for ESCC patients.

Primitive Squamous Cell Carcinoma of Pterygopalatine Fossa

2018 ◽  
Vol 29 (3) ◽  
pp. e298-e300
Author(s):  
Olivier Mauvais ◽  
Cécile Badet ◽  
Laetitia Lestrade ◽  
Laurent Tavernier
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Pterygopalatine Fossa

scholarly journals Δ133p53/FLp53 predicts poor clinical outcome in esophageal squamous cell carcinoma

2019 ◽  
Author(s):  
Qimin Tu ◽  
Hongjian Gong ◽  
Chunhui Yuan ◽  
Gao Liu ◽  
Jinqi Huang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Progression ◽  
Squamous Cell ◽  
Cox Regression ◽  
Tumor Resection ◽  
Serum Samples ◽  
Roc Curve Analysis ◽  
Recurrence Rates

Abstract Background p53 isoform Δ133p53 is directly transactivated by p53 and antagonizes p53 activities in cancer progression. However, its correlation with prognosis and cancer recurrence in esophageal squamous cell carcinoma (ESCC) is still unclear.Methods Expression of Δ133p53 and Δ133p53/full-length p53 (FLp53) in tissues and serums of 180 ESCC patients was evaluated using qRT-PCR.Results Tissue Δ133p53 expression and Δ133p53/FLp53 ratio were significantly increased in ESCC tissue compared with adjacent normal tissue. Pre-operative Δ133p53 expression and Δ133p53/FLp53 ratio in tissue or serum samples were positively associated with TNM stage and post-operative recurrence. Kaplan-Meier curve and multivariate cox regression analyses revealed that the tissue and serum Δ133p53/FLp53 ratio (cutoff value: 2.9160) were independent prognostic factors for overall survival (OS) and progression-free survival (PFS) in ESCC patients, and showed no statistical difference in receiver-operating characteristic (ROC) curve analysis, while serum Δ133p53 showed no significant prognostic value. More importantly, the serum Δ133p53/FLp53 ratio in ESCC patients was significantly decreased within 72 h post tumor resection and patients with a consistently high serum Δ133p53/FLp53 ratio (≥ 2.9160) had higher recurrence rates than those with consistently low ratio values. In addition, dynamic detection in each follow-up timepoint showed that serum Δ133p53/FLp53 ratios were higher than 2.9160 upon recurrence, and they even increased prior to radiologic progression.Conclusion The serum Δ133p53/FLp53 ratio can be a novel predictor for survival outcome and may serve as a real-time parameter for monitoring recurrence in ESCC patients after surgery.

scholarly journals Primary squamous cell carcinoma of the endometrium in a woman of reproductive age: a rare case report

2018 ◽  
Vol 46 (8) ◽  
pp. 3417-3421 ◽  
Author(s):  
Qi Wu ◽  
Zhaoping Chu ◽  
Hua Han ◽  
Suning Bai ◽  
Wenfei Wu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Good Condition ◽  
Tumor Resection ◽  
Stage Iv ◽  
Reproductive Age ◽  
Vaginal Mass ◽  
Rare Case Report ◽  
History Of

Primary endometrial squamous cell carcinoma is an extremely rare tumor that tends to occur in postmenopausal women. We report on a 33-year-old woman who presented with a history of irregular vaginal bleeding for more than 2 years, and a vaginal mass for more than 1 month. Biopsy of the vaginal mass revealed an invasive poorly differentiated squamous cell carcinoma. The patient underwent radical hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic lymph node dissection, peritoneal sampling and vaginal tumor resection. On the basis of her medical history, auxiliary examination and postoperative pathology, the patient was diagnosed with stage IV endometrial squamous cell carcinoma. The patient was followed-up regularly and remained in good condition.

scholarly journals Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2835
Author(s):  
Marco Ferrari ◽  
Stefano Taboni ◽  
Andrea Luigi Camillo Carobbio ◽  
Enzo Emanuelli ◽  
Roberto Maroldi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Neoadjuvant Treatment ◽  
Particle Therapy ◽  
Current Evidence ◽  
Sinonasal Cancer ◽  
Transnasal Approach ◽  
Epithelial Cancers ◽  
Results Management

Sinonasal squamous cell carcinoma is a rare tumor affecting the nasal cavity and paranasal sinuses. Several aspects of this disease, ranging from epidemiology to biology, pathology, diagnosis, staging, treatment, and post-treatment surveillance are controversial, and consensus on how to manage this sinonasal cancer is lacking. A narrative literature review was performed to summarize the current evidence and provide the reader with available data supporting the decision-making process in patients affected by sinonasal squamous cell carcinoma, alongside the authors’ personal opinion on the unsolved issues of this tumor. The review has highlighted several advances in molecular definition of epithelial cancers of the sinonasal tract. Surgery represents the pivot of treatment and is performed through an endoscopic transnasal approach whenever feasible. Open surgery is required for a large proportion of cases. Reconstruction of the defect follows principles of skull base and cranio-maxillo-facial reconstruction. Chemotherapy is given as neoadjuvant treatment or concomitantly to radiotherapy. Photon-based radiation therapy has a crucial role in the adjuvant setting. Particle therapy is providing promising results. Management of the neck should be planned based on the presence of clinically appreciable metastases, primary tumor extension, and need for recipient vessels. Biotherapy and immunotherapy are still underexplored therapeutical modalities.

scholarly journals Surgical strategy for squamous cell carcinoma of the external auditory canal: management of locally advanced cases with skull base involvement

2022 ◽  
Author(s):  
Seiya Goto ◽  
Naoki Nishio ◽  
Kenichiro Iwami ◽  
Tadao Yoshida ◽  
Takashi Maruo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Skull Base ◽  
Squamous Cell ◽  
External Auditory Canal ◽  
Locally Advanced ◽  
Tumor Resection ◽  
Surgical Indication ◽  
Good Survival ◽  
Advanced Stage

Objective Surgical indications for advanced-stage squamous cell carcinoma (SCC) of the external auditory canal (EAC) are highly dependent on the skull base surgery team. The aim of this study was to evaluate the surgical outcomes in patients with SCC of the EAC and to clarify the surgical indication of far advanced cases using the T4-subclassification. Methods Patients with SCC of the EAC who underwent curative treatment from 2002-2021 were retrospectively reviewed at our hospital. Clinical and surgical results, including operative data, overall survival (OS), and disease-specific survival (DSS) were analyzed. To clarify the surgical indication for advanced stage, we proposed the T4-subclassification. Results In 46 patients, the tumors were in T1 stage in 8 patients, T2 in 10, T3 in 5, and T4 in 23. The 5-year DSS with T1, T2, T3, and T4 tumors were 100%, 85.7%, 100%, and 61.7%, respectively. No prognostic impacts for margin status were found between the 5-year OS and DSS (p = 0.23 and p = 0.13). Patients with far advanced stage (T4b) tumors were significantly associated with shorter DSS than those with early stage (T1/T2) and advanced stage (T3/T4a) tumors (p = 0.007 and p = 0.03). Conclusion The present study focused on patients with SCC of the EAC at a University hospital over a period of 20-years, especially with skull base involvement, and a T4-subclassification was proposed. Complete tumor resection in an en bloc fashion could help to achieve a good survival rate even in patients with locally advanced tumors.

Sign in / Sign up

Export Citation Format

Share Document